This study is an update of a systematic review of health-related quality-of-life (HRQOL) methodology reporting in non-small-cell lung cancer (NSCLC) randomized controlled trials (RCTs). The objective was to evaluate HRQOL methodology reporting over the last decade and its benefit for clinical decision making.
INTRODUCTION
Lung cancer is the most common cancer worldwide in both incidence and mortality for men and women. In 2008, there were 1,608,823 new cases of lung cancer diagnosed and 1,378,415 lung cancerrelated deaths, accounting for 18.2% of cancer deaths in the world. 1 Incidence rates for men and women are on the increase worldwide. Survival estimates for patients with lung cancer remain poor; the 1-year survival rate of lung cancer is 42%, and the 5-year rate is 16%. Non-small-cell lung cancer (NSCLC) accounts for 85% of all lung cancer diagnoses. 3 For the 60% of patients who present with advanced NSCLC, palliative chemotherapy is the preferred treatment, which results in a significant, albeit small, median survival benefit of 8 to 10 weeks. 4 Further improvements can be obtained by adding biologic agents that target specific molecular pathways of lung carcinogenesis and by segmenting the population of patients with lung cancer into subgroups according to their presumed predominant molecular pathway. 5 However, progress is expected to be incremental at the cost of adverse effects and new toxicities. 6 Therefore, it is important to assess treatment effectiveness both in terms of objective outcomes (eg, progression-free or overall survival [OS] ) and subjective, patientreported outcomes (PROs). This detailed information can help both clinicians and patients to make informed and comprehensive decisions regarding the best available treatments.
PROs are any information self-reported by the patient regarding their functioning or symptoms in relation to their health condition or therapy. Patient-reported health-related quality of life (HRQOL) falls under the umbrella of PROs and covers physical symptoms and functioning domains and usually provides an overall patient evaluation of their health and quality of life. HRQOL measurement in clinical trials provides additional, patient-based information and can be particularly helpful in randomized controlled trials (RCTs), comparing treatments with similar effectiveness (eg, survival) but with different adverse effect profiles. 7 Several publications [8] [9] [10] [11] have raised issues regarding the various aspects of HRQOL reporting in RCTs, such as the concept, measurement, methodology, and interpretation of HRQOL data. These publications have highlighted that although there have been improvements in the past decade, there are still limitations in some areas of reporting of HRQOL results. This paucity of HRQOL information, particularly for new drugs, may have interfered with their implementation in clinical practice (eg, bevacizumab and cetuximab for NSCLC).
12 When the new drug treatment results in only a small benefit in traditional objective outcomes or in equipoise, good HRQOL data that show differences in subjective patient outcomes may influence the process of clinical implementation.
It is critical that HRQOL results in RCTs are reported in a robust and rigorous manner in order to ensure that both clinicians and patients feel confident in using the information when making critical treatment decisions. This systematic literature review was undertaken with the aim of evaluating the reporting standards of HRQOL methodology incorporated in NSCLC RCTs published between April 2002 and July 2010. This review was conducted as a continuation of the systematic review by Bottomley et al 13 published in 2003. Because the previous review found an increase in the quality of HRQOL reporting from 1980 to March 2002, and more guidelines 8 have come out regarding the reporting of HRQOL results, our hypothesis is that there will be a trend showing a continued improvement of both HRQOL methodology and reporting in RCTs for patients with NSCLC. This systematic review evaluates data collected from RCTs on NSCLC published in the past 8 years and compares the findings with those from the previous report.
METHODS
In this systematic literature review, a methodology identical to the one used in the previous review was implemented. Inclusion criteria for the studies evaluated in this review were predefined as RCTs including adult patients (18 years or older) with newly diagnosed NSCLC, regardless of the grade of the tumor, undergoing any anticancer treatment (surgery, chemotherapy, radiotherapy, or a combination). Exclusion criteria were evaluation of psychological interventions or any supplementary treatment other than surgery, chemotherapy or radiotherapy; assessments that were not patient-reported (eg, HRQOL reported by the clinician or other proxies); and studies with fewer than 100 patients at baseline. Substudies focusing only on HRQOL were included, but were reviewed in conjunction with the original publication of the main trial describing the clinical outcomes and the trial design.
Publications that met the inclusion criteria were identified through PubMed using the following search strategy: ( Only articles published in English language journals were used. All identified studies were evaluated by two reviewers, and a third was available as a mediator in case of disagreement. The main evaluation criteria were identical to the ones used previously and comprised four categories: (1) key characteristics of the RCTs, such as time of publication, study location, treatment outline, and main outcomes; (2) trial design aspects relevant to HRQOL end points; (3) the quality of the HRQOL measurements; and (4) statistical analysis and presentation of HRQOL results. The full set of criteria can be seen in Table 1 .
RESULTS

Identified RCTs
A total of 53 NSCLC RCTs published between 2002 and 2010 met the inclusion criteria for this review. The 53 RCTs included a total of 19,956 patients, with study sample sizes ranging from 103 patients to 1,218 patients. This review retrieved a significantly larger number of studies published that involved NSCLC with an HRQOL end point (53 studies over an 8-year span, compared with 29 studies over a 22-year span), as well as more than double the number of patients assessed in the studies reviewed by Bottomley et al 13 (nearly 20,000 compared with 8,500 patients).
We only present direct comparisons with data from the previous review if the evaluation criteria show relevant changes over time. The key comparisons of all key criteria between the two reviews are summarized in Table 1 .
Clinical and Main HRQOL Results
All but one of the RCTs that were found in the current review incorporated outcomes in terms of survival (Table 2, Socinski et al   45   ) .
Of the 52 studies that did address OS differences, 42 (81%) reported that there were no significant OS differences between treatment arms. However, HRQOL was found to be significantly different between treatment arms in 50% of the studies in which no OS difference was found. Significant differences in HRQOL among patients with NSCLC were observed on symptom and functional levels, with the most prominent ones being hair loss, nausea/vomiting, appetite loss, physical and role functioning, and global health status/HRQOL. With regard to the 10 RCTs that did detect significant survival differences, we found that seven of these (70%) demonstrated significant HRQOL differences between treatment arms, covering HRQOL issues that are similar to the ones described above. In five of these studies, better survival was associated with better HRQOL, whereas in two studies better survival was seen, but HRQOL was worse. Table 2 summarizes the key characteristics of the 53 RCTs included in this review. Of the 53 evaluated studies, 72% were published in high-impact peer-reviewed clinical journals such as the Journal of Clinical Oncology, Annals of Oncology, or Lung Cancer. This is an increase when compared with the previous review, in which 66% of the reviewed articles were published in high-impact journals. For seven (13%) of the RCTs, additional HRQOL publications were released (providing an HRQOL sub-article) that included further analysis and detailed description of the HRQOL design and outcomes. The largest percentage of the RCTs were conducted in the United States or Canada (21%), internationally (15%), by Norway and Sweden (11%), and by Italy (9%). RCTs focusing on NSCLC have become much more international in recruitment since 2002. Whereas the largest percentage of RCTs since 2002 (21%) were conducted in the United States and/or Canada, the largest percentage of RCTs in the former study (24%) took place in Italy.
Key Characteristics of the RCTs
Thirty-nine RCTs (74%) appeared to be industry-funded or affiliated with the pharmaceutical industry through one or more of the authors/investigators, whereas in the previous review, only 55% of the studies were industry-funded. Similar to the previous report, the majority of RCTs focused on chemotherapy (90%). Only two studies investigated the effectiveness of radiotherapy, and three studies used a combination of radiotherapy and chemotherapy.
Finally, Table 3 demonstrates demographic characteristics of the patients participating in all 53 RCTs, including age, sex, and-if provided-race. Although the median age varied from 57 to 76 years, the majority of trials included patients from a wide range of ages. As far as we could gather, only three RCTs have exclusively studied elderly patients (age Ͼ 60 years). In most RCTs (96%), the study sample involved more male than female patients. 
Trial Design Aspects Relevant to HRQOL End Points
The RCTs design aspects related to the HRQOL end points such as the method of randomization, HRQOL hypotheses and patient selection criteria are presented in Table 4 . Although all included trials were randomized (this was a key eligibility criterion), 15 studies (28%) did not define the exact randomization procedure. All studies included a statement on the requirement of patient informed consent and specifications of the patient inclusion and exclusion criteria. Almost all trials focused on patients with NSCLC having stage III and/or IV disease, with the exception . ‡Only statistically significant results discussed (P Ͻ .05). In 44 (83%) of the included trials, survival outcomes were predefined as main end points. Only nine studies (17%) reported HRQOL to be a primary end point. An HRQOL hypothesis was rarely mentioned in the publications included in this review, with only eight (15%) of the 53 studies formulating an a priori hypothesis stated in the introduction or statistical analysis sections. These hypotheses described the anticipated differences in general HRQOL between treatment arms. Only seven studies (13%) specifically stated that baseline HRQOL assessment was mandatory for study participation.
When compared with the earlier review, methods of randomization and HRQOL hypotheses were substantially less frequently reported in the RCTs of the current review (a decrease of 11% and 16%, respectively). However, the reporting on informed consent was seen more frequently (an increase of 14% since 2002). Table 5 summarizes the quality of the measurement aspects of HRQOL in the RCTs. In general, HRQOL concepts were measured by using well-known instruments with adequate psychometric properties. The EORTC core questionnaire Quality of Life Questionnaire C30 (QLQ-C30) 76 was the most frequently used instrument. It was used in 57% of the evaluated studies since 2002, compared with 31% in the previous review. In all but two studies, the QLQ-C30 was supplemented with a lung cancer-specific questionnaire: EORTC QLQ-LC13, 77 or an EORTC tool with minor adaptations such as the reported QLQ-LC14 or QLQ-LC17. In one study, the QLQ-LC13 was used without the core questionnaire. The Lung Cancer Symptom Scale 78, 79 and the questionnaires from the Functional Assessment for Chronic Illness Therapy 80 were used in 13% and 23% of the studies, respectively. Other HRQOL instruments included the Visual Analog Scale, the Rotterdam Symptom Checklist, 81 a Symptom Scale covering 14 commonly reported lung cancer symptoms (SS14), the Brief Fatigue Inventory, 82 EuroQol, 83 and the Linear Analog Self Assessment scale. 84 Baseline compliance was reported by the majority of studies (75%). Validity and reliability issues of the instruments were addressed by means of referencing the appropriate validation studies (66% of RCTs). In the remaining 34% of the RCTs, no statement or reference was provided with regard to validity or reliability, although most of the chosen instruments did have sufficient psychometric properties. Six studies (11%) incorporated ad hoc instruments in addition to a validated existing questionnaire. In contrast to the frequent reporting of instrument validity and reliability, the overall number of studies that addressed cultural validity was low. Of the 35 studies that used a translated version of an HRQOL tool in a population that the tool was not originally developed for, 60% failed to report on the cultural validation process or study, regardless of whether or not the instrument was culturally validated.
Quality of the HRQOL Measurements
The domains covered by the questionnaires were considered adequate in 74% of the RCTs in which both symptoms and functional status results were reported. Many of these studies did not formulate a specific research question and thus complicated the evaluation of the reporting adequacy of the domains. Whenever HRQOL, as a general term, was the subject of research, we expected that at least global HRQOL would be addressed. However, 17% percent of the studies addressed physical functioning, but excluded social and/or emotional functioning or merely included symptoms and no domains of functioning at all. Given the multidimensional character of global HRQOL, we rated these latter instruments as limited in their capacity for overall HRQOL assessment. Rationales for selecting the chosen HRQOL instruments were provided in only 8% of the analyzed trials. This is considerably fewer in comparison with the RCTs found between 1980 and 2002, in which 34% reported a rationale for the selected HRQOL instrument. A rationale was defined as present if the authors clearly referred to characteristics of the instrument as a basis for its intended use or if a reason was specified for choosing the particular instrument rather than any other HRQOL instrument.
Details on instrument administration were often left undefined. Ten studies (19%) noted only a few details, such as the place or time of questionnaire completion or the procedure of sending reminders. This is a considerably higher percentage when compared with the RCTs from the previous review, which found no studies that reported any information on this topic at all. However, a second glance showed that only two studies (4%), compared with 10 studies (34%) reported in Bottomley et al, 13 explained that help would be provided by relatives or a research assistant for patients unable to complete the assessment independently. All but three studies (94%) reported the timing of HRQOL assessments. Table 6 summarizes details regarding the reporting of HRQOL analysis and results in the NSCLC clinical trials. Overall, the studies specified the statistical tests used to investigate the significance of between-treatment HRQOL difference (91%), which shows an increase of 15% when compared with the RCTs studied in the previous review (76%). Out of the 49 RCTs in which a test of statistical significance was reported, 56% demonstrated significant differences in HRQOL scores, which is notably less than was seen in the previous review (68%). Only 30% of all evaluated Abbreviations: HRQOL, health-related quality of life; NSCLC, non-small-cell lung cancer.
Statistical Analysis and Presentation of HRQOL Results
‫ء‬
Assessed if indicated that patients were randomly assigned centrally or if the randomization method was explicitly stated. †Overall number of patients enrolled onto the trial. When the number of patients registered was not available, the number of patients randomly assigned was listed. ‡Assessed if authors had a pretrial hypothesis on possible HRQOL changes (eg, related to specific domains). studies reported and discussed the clinical significance of the observed HRQOL differences. These studies included prespecifications regarding the minimum amount of change that is required to define a response in HRQOL that is meaningful to the patient. The evaluation of clinical meaningfulness provides an added value to studies involving HRQOL.
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The presentation of the results was considered adequate if the authors provided detailed descriptions of the outcome scores, supported by graphs or tables; if the results were compared with outcomes from related research, or conclusions were drawn based on the currently investigated therapies and HRQOL; and if these were followed by implications for clinical practice. Results of the review found that, of the 53 studies, 62% met the criteria for adequate reporting of HRQOL, and 32% reported only brief HRQOL details without interpretation and were labeled as having limited information presented on HRQOL. In addition, two studies explained that further reporting of HRQOL would be presented in future reports.
Of the 53 RCTs evaluated in this review, 62% reported adequate information with regard to compliance or "missingness." These studies had mentioned the issue of missing data or had listed compliance percentages or numbers according to treatment arm. Due to the lack of missing data reported specific to each treatment arm, 11% of the 53 studies were classified as having limited presentation of missing data, and 26% presented no data at all. Noncompliance, when reported, was due to death, deterioration of health, or institution error.
DISCUSSION
The aim of this review was to examine the developments in HRQOL assessments and reporting of results in RCTs in NSCLC since 2002, as well as to determine whether the findings may support physicians and patients in clinical decision making. Results from this updated systematic review are best interpreted in comparison with those of the previous systematic review covering RCTs between 1980 and 2002.
Overall, we observed an increase in the number of NSCLC RCTs that involved HRQOL measurement and that were published in high-impact journals, thus reaching the clinical community. The studies were geographically more widespread and multinational and more frequently supported by commercial sponsors over recent times.
The increase in industry-funded trials could be explained by the significant increase in the cost of conducting clinical trials, 86 making it difficult for academic groups and individual centers to conduct largescale RCTs. Another reason may be related to the rapid development and evaluation in the past decade of promising new targeted therapies, some of which have been tested in NSCLC, such as erlotinib. Our results show that recently, almost all studies focused on the effects of systemic treatments alone rather than on radiotherapy alone or radiotherapy plus systemic treatments. This again may reflect the increased clinical evaluation of new targeted therapies. Encouragingly, some aspects of the HRQOL methodology reporting in RCTs for NSCLC have improved. This review has found an increase in the reporting of formal statistical tests in HRQOL analyses and of the clinical significance and meaning of the results. The increased frequency of use of the EORTC QLQ-C30 suggests that it is becoming the tool of choice for use in NSCLC RCTs. It includes many of the characteristics defined by the current Guidance for Industry, which should be part of an effective HRQOL PRO assessment tool (eg, adequacy of both validity and reliability). 87 Unfortunately, other aspects of reporting HRQOL methodology did not improve over time, and some even showed deterioration. For example, the limited reporting of missing HRQOL data was addressed in the previous systematic review and continued to be a problem in the present review. Although most of the studies were considered to have addressed the issue of missing data appropriately, the standards for critical evaluation were difficult to determine as a result of huge variability between the RCTs in the way that the missing data were reported or the level of detail included. Not adjusting for missing data often limits the robustness of the results and reduces confidence in the HRQOL conclusions. The reporting of missing data by treatment arm and over time needs to be standardized to aid in the interpretation of the final HRQOL results. It should be acknowledged that journal space is often limited, and authors may not have been able to report missing data in full detail.
Reporting of a priori hypotheses of HRQOL and reporting on the rationale for instruments used has decreased by almost a half from the previous review. This trend is a huge concern, because defining an a priori hypothesis is an essential requirement of a good study design and helps to reduce multiple testing of HRQOL variables and chance findings. The infrequent reporting on rationale for the use of a particular HRQOL instrument is probably related to availability of well-validated standard HRQOL tools, which are becoming the instruments of choice (such as the EORTC or Functional Assessment of Cancer Therapy questionnaires). Ideally authors should still outline the reasons for using a specific instrument on the basis of their a priori hypothesis. However, we recognize that this is mainly relevant in cases in which the selected HRQOL tools are not considered standard or widely accepted.
Our study has several limitations. A weakness of our systematic review procedure was the need for subjective judgments on several of the evaluation criteria. For example, evaluating whether a study adequately reported missing data and HRQOL domains or whether a study had appropriately reported the cultural validity of the HRQOL instrument is difficult because of the differences in interpretations of the preset definitions of adequate versus limited reporting. Nevertheless, using two reviewers helped to standardize our assessments, and only rarely was there a significant disagreement between the reviewers. We did not approach the authors of the RCTs, who may have had additional information on the HRQOL data, as the objective of this study was to review the quality of reporting of HRQOL in the published RCTs, rather than the actual RCT itself. This literature review focused on RCTs published in English only, so five studies published in Chinese were excluded. Finally, RCTs evaluating surgical interventions were absent in this review. This was due to the fact that such trials were published in a language different from English, were not randomized, or had small patient samples (Ͻ 100).
In conclusion, results from the comparison of this review to the earlier one of Bottomley et al 13 provide evidence that overall the quality and frequency of HRQOL reporting in NSCLC RCTs has increased since 2002. The clinical effectiveness of systemic treatments in NSCLC is unfortunately still limited, and therefore it is crucial to consider the impact on patient HRQOL when making difficult treatment decisions. This is evident in our review, which shows that HRQOL has become a major secondary end point included in numerous NSCLC RCTs. We encourage continued improvement in the methodology and reporting of HRQOL studies, specifically the need for defining a priori hypothesis and detailed reporting of missing data and its potential impact on interpretation of HRQOL results. Although the inclusion and presentation of HRQOL results has improved over the past decade, it still requires further development. We reiterate our recommendation for the development of a CONSORT-style checklist to ensure that all necessary HRQOL data are reported in a standardized manner. We believe that HRQOL data are being used to alter clinical practice and that future reporting standards will improve the added value of HRQOL data in NSCLC RCTs.
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